tirzepatide news november 2025 People Who Stopped Taking the Weight Loss Drug Regained Nearly Half the Weight They Lost Eli Lilly H1 2025: Tirzepatide

To view or add a comment, sign in 1 in 10 employers likely to drop GLP-1 coverage next year: report 1 in 10 U.S

Ongoing Support and Optimization Throughout Your Journey The consultation doesnt end once your protocol begins

In rare cases where GLP-1 causes intolerable reflux despite all interventions, your provider may recommend discontinuationbut this is not the typical outcome

This is particularly relevant for significant injuries, post-surgical recovery, chronic conditions that have resisted single-agent approaches, or patients dealing with both musculoskeletal and inflammatory components simultaneously

Some patients lost more than 20 percent of body weight during long term treatment